Kaiser Permanente, union coalition reach tentative deal after strike
Kaiser Permanente researchers have good news for patients, surgeons, anesthesiologists, and hospital administrators who have had to put off elective...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today highlighted a new analysis suggesting that the Moderna COVID-19 vaccine is highly effective against circulating variants of concern, including in a vaccine effectiveness study conducted in partnership with Kaiser Permanente Southern California (KPSC) and in a separate recent publication by the U.S. Centers for Disease Control and Prevention (CDC). Additionally, the Company shared a new analysis of follow-up through 1 year in the Phase 3 COVE study suggesting a lower risk of breakthrough infection in participants vaccinated more recently (median 8 months after first dose) compared to participants vaccinated last year (median 13 months after first dose). Manuscripts summarizing both findings have been posted to preprint servers and will be submitted for peer-reviewed publication.
OAKLAND, Calif., Aug. 12, 2020 /PRNewswire/ -- Today, Kaiser Permanente began participating in a phase 3 clinical trial to test an investigational vaccine against SARS-CoV-2, the virus causing the current COVID-19 global pandemic. Kaiser Permanente plans to enroll approximately 1,400 participants at 4 sites in California and Oregon. The goal for this trial is to enroll up to 30,000 participants at more than 120 sites around the world. The investigational vaccine being tested in this trial is BNT162b2, one of the vaccine candidates in development by Pfizer, Inc., and BioNTech, which are also the sponsors of the study.
OAKLAND, Calif., JUNE 18, 2020 — Kaiser Permanente, the nation’s largest nonprofit, integrated health system, announced that it is joining with nonprofit Civica Rx in its mission of assuring that health providers nationally have access to stable and affordable supplies of essential generic medications throughout the COVID-19 pandemic and beyond.
Kaiser Permanente, the large health insurer and hospital operator, is joining the nonprofit drug company Civica Rx in a key role in the third year of the effort to create lower cost prescriptions that include medicines to treat the coronavirus strain Covid-19.